Genetic Risk Factors and Mendelian Randomization in Cardiovascular Disease

Current Cardiology Reports

Volumn 17, Issue 5, 2015, Pages

  Swerdlow, Daniel I ^a   Hingorani, Aroon D ^a   Humphries, Steve E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular disease; Causal inference; Genetics; Mendelian randomisation; Risk factors; Risk prediction

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN (PROTEIN); TOCILIZUMAB; TORCETRAPIB; VARESPLADIB;

ABDOMINAL AORTA ANEURYSM; ALCOHOL CONSUMPTION; APOB GENE; BLOOD PRESSURE; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CAUSAL ATTRIBUTION; CEREBROVASCULAR ACCIDENT; COL4A1 COL4A2 GENE; CONFOUNDING VARIABLE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; ELECTROCARDIOGRAM; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENETICS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; IL6R GENE; INFLAMMATION; ISCHEMIC HEART DISEASE; LDLR GENE; LIPID BLOOD LEVEL; LPL GENE; MENDELIAN RANDOMIZATION ANALYSIS; PATHOGENESIS; PCSK9 GENE; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; QRS COMPLEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SLC22A3 LPAI2 LPA GENE; SMOKING; SORT1 GENE; SYSTEMATIC ERROR; VALVULAR HEART DISEASE;

BIOMARKERS; CARDIOVASCULAR DISEASES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MENDELIAN RANDOMIZATION ANALYSIS; RISK FACTORS;

EID: 84928319979     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-015-0584-x     Document Type: Review

References (103)

1. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.
2. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336:1475–82.
3. Fox KAA, Fitzgerald G, Puymirat E, Huang W, Carruthers K, Simon T, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014;4:e004425.
4. Brotman DJ, Walker E, Lauer MS, O’Brien RG. In search of fewer independent risk factors. Arch Intern Med. 2005;165:138–45.
5. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000.
6. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014;383:1899–911.
7. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–40.
8. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008;5:e78.
9. Seshasai SRK, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.
10. Fruchart J-C, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26.
11. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478–90a. Recent European guidance on the clinical management of familial hypercholesterolaemia.
12. Futema M, Plagnol V, Li K, Whittall RA, Neil HAW, Seed M, et al. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations. J Med Genet. 2014;51:537–44.
13. Fouchier SW, Dallinga-Thie GM, Meijers JCM, Zelcer N, Kastelein JJP, Defesche JC, et al. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res. 2014;115:552–5. Report of a novel locus responsible for causing familial hypercholesterolaemia.
14. Lange LA, Hu Y, Zhang H, Xue C, Schmidt EM, Tang Z-Z, et al. Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet. 2014;94:233–45. Demonstration of the use of whole-exome sequencing for investigating genetic determinants of atherosclerosis and coronary heart disease.
15. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JPA, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet. 2008;9:356–69. A guide to the development, application and utility of genome-wide association studies.
16. Hindorff LA, Junkins HA, Hall P, Mehta JP, Manolio TA. A catalog of published genome-wide association studies [Internet]. Cat Publ Genome-Wide Assoc Stud. [cited 2011 Jun 30]. Available from: www.genome.gov/gwastudies.
17. Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2012;45:25–33. The largest meta-analysis of genome-wide association studies of coronary heart disease published to date.
18. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161–9.
19. Arsenault BJ, Boekholdt SM, Dubé M-P, Rhéaume E, Wareham NJ, Khaw K-T, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet. 2014;7:304–10.
20. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–9.
21. Tarasov KV, Sanna S, Scuteri A, Strait JB, Orrù M, Parsa A, et al. COL4A1 is associated with arterial stiffness by genome-wide association scan. Circ Cardiovasc Genet. 2009;2:151–8.
22. Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann J, Shah T, Sofat R, et al. The interleukin-6 receptor as a potential target for coronary heart disease prevention: evaluation using Mendelian randomisation. Lancet. 2012;2012. A Mendelian randomisation study of the interleukin-6 receptor as a potential therapeutic target in coronary disease, providing evidence that this pathway has a causal role and may hold benefit for disease prevention. Findings were corroborated in a similar study by Sarwar et al., below.
23. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205–13. A Mendelian randomisation study of the interleukin-6 receptor as a potential therapeutic target in coronary disease, providing evidence that this pathway has a causal role and may hold benefit for disease prevention. Findings were corroborated in a similar study by Swerdlow et al.
24. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45:1274–83.
25. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. [Internet]. 2011 [cited 2011 Mar 13]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/21378990.
26. Peden JF, Hopewell JC, Saleheen D, Chambers JC, Hager J, Soranzo N, et al. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet. 2011;43:339–44.
27. Johnson AD, Hwang S-J, Voorman A, Morrison A, Peloso GM, Hsu Y-H, et al. Resequencing and clinical associations of the 9p21.3 region: a comprehensive investigation in the Framingham heart study. Circulation. 2013;127:799–810.
28. Roberts R, Stewart AFR. 9p21 and the genetic revolution for coronary artery disease. Clin Chem. 2012;58:104–12.
29. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103–9. A large genome-wide association study reporting common genetic determinants of blood pressure.
30. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42:937–48. A very large genome-wide association study reporting novel genetic determinants of obesity-related traits.
31. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet. 2010;42:436–40.
32. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet. 2012;44:670–5.
33. Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, et al. Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet. 2010;42:240–4.
34. Butler AM, Yin X, Evans DS, Nalls MA, Smith EN, Tanaka T, et al. Novel loci associated with PR interval in a genome-wide association study of 10 African American cohorts. Circ Cardiovasc Genet. 2012;5:639–46.
35. Sotoodehnia N, Isaacs A, de Bakker PIW, Dörr M, Newton-Cheh C, Nolte IM, et al. Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet. 2010;42:1068–76.
36. Ritchie MD, Denny JC, Zuvich RL, Crawford DC, Schildcrout JS, Bastarache L, et al. Genome- and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. Circulation. 2013;127:1377–85.
37. Pfeufer A, van Noord C, Marciante KD, Arking DE, Larson MG, Smith AV, et al. Genome-wide association study of PR interval. Nat Genet. 2010;42:153–9.
38. Chambers JC, Zhao J, Terracciano CMN, Bezzina CR, Zhang W, Kaba R, et al. Genetic variation in SCN10A influences cardiac conduction. Nat Genet. 2010;42:149–52.
39. Holm H, Gudbjartsson DF, Arnar DO, Thorleifsson G, Thorgeirsson G, Stefansdottir H, et al. Several common variants modulate heart rate, PR interval and QRS duration. Nat Genet. 2010;42:117–22.
40. Smith JG, Avery CL, Evans DS, Nalls MA, Meng YA, Smith EN, et al. Impact of ancestry and common genetic variants on QT interval in African Americans. Circ Cardiovasc Genet. 2012;5:647–55.
41. Chang K-C, Barth AS, Sasano T, Kizana E, Kashiwakura Y, Zhang Y, et al. CAPON modulates cardiac repolarization via neuronal nitric oxide synthase signaling in the heart. Proc Natl Acad Sci. 2008;105:4477–82.
42. Smith NL, Felix JF, Morrison AC, Demissie S, Glazer NL, Loehr LR, et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ Cardiovasc Genet. 2010;3:256–66.
43. Villard E, Perret C, Gary F, Proust C, Dilanian G, Hengstenberg C, et al. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J. 2011;32:1065–76.
44. Arnett DK, Li N, Tang W, Rao DC, Devereux RB, Claas SA, et al. Genome-wide association study identifies single-nucleotide polymorphism in KCNB1 associated with left ventricular mass in humans: the HyperGEN Study. BMC Med Genet. 2009;10:43.
45. Del Greco MF, Pattaro C, Luchner A, Pichler I, Winkler T, Hicks AA, et al. Genome-wide association analysis and fine mapping of NT-proBNP level provide novel insight into the role of the MTHFR-CLCN6-NPPA-NPPB gene cluster. Hum Mol Genet. 2011;20:1660–71.
46. Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–12.
47. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470–7.
48. Trégouët D-A, König IR, Erdmann J, Munteanu A, Braund PS, Hall AS, et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet. 2009;41:283–5.
49. Dichgans M, Malik R, König IR, Rosand J, Clarke R, Gretarsdottir S, et al. Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke J Cereb Circ. 2014;45:24–36. A valuable comparison between the common genetic determinants of stroke and coronary heart disease highlighting shared aetiological pathways.
50. Traylor M, Farrall M, Holliday EG, Sudlow C, Hopewell JC, Cheng Y-C, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol. 2012;11:951–62.
51. Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RAP, et al. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet. 2002;360:1531–9.
52. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491–3.
53. Helgadottir A, Thorleifsson G, Magnusson KP, Grétarsdottir S, Steinthorsdottir V, Manolescu A, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40:217–24.
54. Harrison SC, Kalea AZ, Holmes MV, Agu O, Humphries SE. Genomic research to identify novel pathways in the development of abdominal aortic aneurysm. Cardiol Res Pract. 2012;2012:852829.
55. Gretarsdottir S, Baas AF, Thorleifsson G, Holm H, den Heijer M, de Vries J-PPM, et al. Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet. 2010;42:692–7.
56. Bown MJ, Jones GT, Harrison SC, Wright BJ, Bumpstead S, Baas AF, et al. Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. Am J Hum Genet. 2011;89:619–27.
57. Bradley DT, Hughes AE, Badger SA, Jones GT, Harrison SC, Wright BJ, et al. A variant in LDLR is associated with abdominal aortic aneurysm. Circ Cardiovasc Genet. 2013;6:498–504.
58. Harrison SC, Smith AJP, Jones GT, Swerdlow DI, Rampuri R, Bown MJ, et al. Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur Heart J. 2012;34:3707–16.
59. Hayden EC. Technology: the $1,000 genome. Nature. 2014;507:294–5.
60. Holmes MV, Harrison S, Talmud PJ, Hingorani AD, Humphries SE. Utility of genetic determinants of lipids and cardiovascular events in assessing risk. Nat Rev Cardiol. 2011;8:207–21. A comprehensive review of the underlying research and clinical utility of using genetics for predicting cardiovascular disease risk.
61. Ashley EA, Butte AJ, Wheeler MT, Chen R, Klein TE, Dewey FE, et al. Clinical assessment incorporating a personal genome. Lancet. 2010;375:1525–35.
62. Ganna A, Magnusson PKE, Pedersen NL, de Faire U, Reilly M, Arnlöv J, et al. Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol. 2013;33:2267–72.
63. Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33:2261–6.
64. Hughes MF, Saarela O, Stritzke J, Kee F, Silander K, Klopp N, et al. Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts. PLoS One. 2012;7:e40922.
65. Brautbar A, Pompeii LA, Dehghan A, Ngwa JS, Nambi V, Virani SS, et al. A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies. Atherosclerosis. 2012;223:421–6.
66. Hernesniemi JA, Seppälä I, Lyytikäinen L-P, Mononen N, Oksala N, Hutri-Kähönen N, et al. Genetic profiling using genome-wide significant coronary artery disease risk variants does not improve the prediction of subclinical atherosclerosis: the Cardiovascular Risk in Young Finns Study, the Bogalusa Heart Study and the Health 2000 Survey—a meta-analysis of three independent studies. PLoS One. 2012;7:e28931.
67. Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376:1393–400. A clinically focused report of a study investigating the incorporation of genetic information into coronary heart disease risk prediction.
68. Humphries SE, Drenos F, Ken-Dror G, Talmud PJ. Coronary heart disease risk prediction in the era of genome-wide association studies: current status and what the future holds. Circulation. 2010;121:2235–48.
69. Annas GJ, Elias S. 23andMe and the FDA. N Engl J Med. 2014;370:985–8.
70. Davey Smith G, Ebrahim S. “Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1–22. A guide to the theoretical and practical basis of Mendelian randomisation.
71. Ebrahim S, Davey Smith G. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet. 2008;123:15–33. A review of the role of Mendelian randomisation in overcoming some of the limitations of traditional epidemiology.
72. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.
73. Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ. 2013;347:f5680.
74. Myung S-K, Ju W, Cho B, Oh S-W, Park SM, Koo B-K, et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;346:f10.
75. Hingorani A, Humphries S. Nature’s randomised trials. Lancet. 2005;366:1906–8. A concise introduction to the similarities between Mendelian randomisation and the traditional randomised controlled trial.
76. Mendel G. Experiments in plant-hybridisation. Brunn Nat Hist Soc. 1865. Gregor Mendel’s seminal work on the inheritance of pea plant characteristics. The seminal description of the laws of what has become known as ‘Mendelian’ inheritance. These underly the Mendelian randomisation principle.
77. Linsel-Nitschke P, Götz A, Erdmann J, Braenne I, Braund P, Hengstenberg C, et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease—a Mendelian Randomisation study. PLoS One. 2008;3:e2986.
78. Ference BA, Julius S, Mahajan N, Levy PD, Williams KA, Flack JM. Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension. Hypertension. 2014;63:1182–8.
79. Luke MM, Kane JP, Liu DM, Rowland CM, Shiffman D, Cassano J, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27:2030–6.
80. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634–9. A large-scale Mendelian randomisation study implicating triglyceride-mediated aetiological pathways in the development of coronary heart disease.
81. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2014. Report of a study using Mendelian randomisation techniques to investigate the causal contributions of major blood lipid fractions in coronary heart disease.
82. Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345–52. An innovative Mendelian randomisation study using novel techniques to investigate further the causal contributions of plasma triglycerides in coronary disease.
83. Hafiane A, Genest J. HDL, atherosclerosis, and emerging therapies. Cholesterol. 2013;2013:891403. A review discussing the controversial role of HDL cholesterol in coronary heart disease and the potential utility of pharmacological modulation of HDL-C.
84. Frikke-Schmidt R, Nordestgaard BG, Stene MCA, Sethi AA, Remaley AT, Schnohr P, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299:2524–32.
85. Haase CL, Tybjærg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab. 2012;97:E248–56.
86. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet [Internet]. 2012 [cited 2012 Jun 2]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/22607825. An important Mendelian randomisation study providing evidence that one aspect of HDL cholesterol metabolism appears not to have a causal role in the development of coronary heart disease.
87. Hansson GK. Atherosclerosis—an immune disease: the Anitschkov Lecture 2007. Atherosclerosis. 2009;202:2–10.
88. Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, et al. Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548. A large collaborative Mendelian randomisation study providing strong evidence against a causal role for C-reactive protein in coronary heart disease.
89. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst. Rev. Online. 2010;CD008331
90. Holmes MV, Lange LA, Palmer T, Lanktree MB, North KE, Almoguera B, et al. Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. Am J Hum Genet. 2014;94:198–208. An allele score-based Mendelian randomisation study investigating the causal contribution of body mass index—a complex phenotype—in other areas of cardiometabolic disease.
91. Nordestgaard BG, Palmer TM, Benn M, Zacho J, Tybjærg-Hansen A, Davey Smith G, et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med. 2012;9:e1001212.
92. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. 2011;342:d671.
93. Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2014;349:g4164. A landmark genetic investigation of the much-debated causal role of alcohol consumption in a range of cardiometabolic disease phenotypes.
94. Landry Y, Gies J-P. Drugs and their molecular targets: an updated overview. Fundam Clin Pharmacol. 2008;22:1–18.
95. Nicholls SJ, Cavender MA, Kastelein JJP, Schwartz G, Waters DD, Rosenson RS, et al. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc Drugs Ther. 2012;26:71–5.
96. Holmes MV, Simon T, Exeter HJ, Folkersen L, Asselbergs FW, Guardiola M, et al. Secretory phospholipase A2-IIA and cardiovascular disease: a Mendelian randomization study. J Am Coll Cardiol. 2013;62(21):1966–76.
97. Nicholls SJ, Kastelein JJP, Schwartz GG, Bash D, Rosenson RS, Cavender MA, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014;311:252–62.
98. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505–15.
99. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.
100. Sofat R, Hingorani AD, Smeeth L, Humphries SE, Talmud PJ, Cooper J, et al. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation. 2010;121:52–62. A novel application of Mendelian randomisation for investigating adverse drug effects, providing evidence that the hypertensive effect of torcetrapib therapy was an off-target action of the drug.
101. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42. A large meta-analysis of randomised trials demonstrating the increased risk of new-onset type 2 diabetes with statin treatment.
102. Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–64. Corroboration of the increased diabetes risk with statin therapy, showing that high-intensity statin therapy led to the greatest risk of diabetes.
103. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. The Lancet [Internet]. 2014 [cited 2014 Sep 24]; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673614611831. A study using data from randomised trials and Mendelian randomisation to investigate the aetiology of the increased risk of diabetes with statin therapy.